GlassScriptPhysician profile
George M Kosco
NPI 1699774695
$4,256.63
in general payments reported to CMS, 2019-2025
39 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $720 · 2021: $1,055 · 2022: $503 · 2023: $302 · 2024: $353 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $533.18 | 2019-2025 | |
| Lilly USA, LLC | $521.62 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Astrazeneca Pharmaceuticals LP | $399.70 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $399.44 | 2019-2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $210.31 | 2019-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $200.05 | 2019-2021 | |
| Amgen INC. | $177.30 | 2019-2023 | Repatha, Otezla |
| Astellas Pharma US INC | $176.98 | 2020-2021 | |
| Daiichi Sankyo INC. | $174.62 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $162.49 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $149.56 | 2019-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.01 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $119.24 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $88.75 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $78.93 | 2024-2025 | Voquezna |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Kosco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.